Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 3 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 17Leukemia 12Breast Neoplasms 12Prostatic Neoplasms 10Neoplasm Metastasis 8Recurrence 6Pancreatic Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Philadelphia Chromosome 4Multiple Myeloma 4Lymphoma 4Burkitt Lymphoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Ovarian Neoplasms 3Glioma 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neuroblastoma 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Cyclophosphamide 108Rituximab 62Etoposide 56Methotrexate 52Cytarabine 52Peripheral Blood Stem Cell Transplantation 47Vincristine 45Filgrastim 43fludarabine phosphate 41Radiotherapy 37Mycophenolic Acid 35Doxorubicin 35Tacrolimus 33Busulfan 33Whole-Body Irradiation 32Prednisone 31Methylprednisolone 27Antilymphocyte Serum 27Dexamethasone 26Cyclosporine 26Melphalan 24merphos 20blinatumomab 20Leucovorin 20Granulocyte Colony-Stimulating Factor 16Carmustine 15fludarabine 14Ifosfamide 14Calcium Dobesilate 14CT-P10 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Burkitt Lymphoma × Dasatinib × Clear all
NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
222 enrolled
Lymphoid

Burkitt Lymphoma

NCT00792948 2026-05-29

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
97 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02143414 2026-05-28

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
53 enrolled 12 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02420717 2025-06-08

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled 13 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡